Why the study?
Severe mental illness is linked to elevated cardiovascular risk, and dyslipidaemia is a modifiable risk factor that may be inadequately managed in this population.
Is the management of dyslipidaemia (lipid-profile measurements, presence of dyslipidaemia, and redemption of lipid-lowering pharmacotherapy) different in patients with severe mental illness compared to healthy controls?
Is the management of dyslipidaemia (lipid-profile measurements, presence of dyslipidaemia, and redemption of lipid-lowering pharmacotherapy) different in patients with severe mental illness compared to healthy controls?
While there is increased awareness of managing dyslipidaemia for primary prophylaxis in patients with severe mental illness, secondary prevention with lipid-lowering drugs in high-risk patients may be lacking.
May signal undertreatment gaps in severe mental illness; leaves open causal mechanisms and needs prospective trials before guiding practice.
Background: Severe mental illness (SMI) is associated with increased cardiovascular risk. Dyslipidaemia is a potentially modifiable risk factor, which may be inadequately managed in patients with SMI. Objectives: healthy controls (HCs) in 2005 and 2015. Design and methods: Using Danish registers, we identified adult patients with SMI in the Greater Copenhagen Area (schizophrenia spectrum disorders or bipolar disorder) with ⩾1 general practitioner contact in the year before 2005 and 2015, respectively, and HCs without SMI matched on age and gender (1:5). Outcomes were lipid-profile measurements, presence of dyslipidaemia and redemption of lipid-lowering pharmacotherapy. Differences in outcomes between patients with SMI and controls were measured with multivariable logistic regression. Results: 0.61 (99% CI 0.41-0.89)]. Conclusion: These results imply an increased general awareness of managing dyslipidaemia among patients with SMI in the primary prophylaxis of cardiovascular disease. However, secondary prevention with lipid-lowering drugs in patients with SMI at high cardiovascular risk may be lacking.
No takes yet. Share an insight, caveat, or question.
Mohr et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: